BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28566530)

  • 1. Rationale for the development of alternative forms of androgen deprivation therapy.
    Kumari S; Senapati D; Heemers HV
    Endocr Relat Cancer; 2017 Aug; 24(8):R275-R295. PubMed ID: 28566530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
    Biron E; Bédard F
    J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.
    Liu S; Kumari S; Hu Q; Senapati D; Venkadakrishnan VB; Wang D; DePriest AD; Schlanger SE; Ben-Salem S; Valenzuela MM; Willard B; Mudambi S; Swetzig WM; Das GM; Shourideh M; Koochekpour S; Falzarano SM; Magi-Galluzzi C; Yadav N; Chen X; Lao C; Wang J; Billaud JN; Heemers HV
    Elife; 2017 Aug; 6():. PubMed ID: 28826481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
    Wang G; Sadar MD
    J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
    Elbanna M; Heemers HV
    Discov Med; 2014 May; 17(95):267-74. PubMed ID: 24882718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor structural and functional elements: role and regulation in prostate cancer.
    Dehm SM; Tindall DJ
    Mol Endocrinol; 2007 Dec; 21(12):2855-63. PubMed ID: 17636035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer.
    Shiota M; Song Y; Takeuchi A; Yokomizo A; Kashiwagi E; Kuroiwa K; Tatsugami K; Uchiumi T; Oda Y; Naito S
    J Urol; 2012 Feb; 187(2):707-14. PubMed ID: 22177207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
    Culig Z; Santer FR
    Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heavy ion radiotherapy for prostate cancer -- the role of hormone therapy].
    Suzuki K; Matsui H; Kawamura H; Ohno T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):159-63. PubMed ID: 25743135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action.
    DePriest AD; Fiandalo MV; Schlanger S; Heemers F; Mohler JL; Liu S; Heemers HV
    Database (Oxford); 2016; 2016():. PubMed ID: 26876983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
    BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
    Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.